Novo Nordisk (NYSE:NVO) Could Be 61% Undervalued Following Rising GLP 1 Competition

Eli Lilly trial data showing retatrutide outperforming Ozempic has sharpened the competitive focus on Novo Nordisk (NYSE:NVO), just as the Danish drugmaker outlines longer term 2030 goals. Novo Nordisk's share price has reacted sharply to this rising GLP-1 competition, with a 1-day share price return of 2.20% and 30-day share price return of 5.51%. These sit against a year-to-date share price decline of 23.65% and a 3-year total shareholder return down 56.69%, which signals fading momentum despite a short-term bounce. Scan how Novo Nordisk compares with other potential GLP-1 and healthcare contenders by reviewing our curated list of 34 healthcare AI stocks in this space.